Neuroendocrine Tumours Treatment Market Report and Forecast 2025-2034
Description
The neuroendocrine tumours treatment market was valued at USD 2.45 Billion in 2024, driven by the rising incidence of neuroendocrine tumours and advancements in treatment modalities across the 8 major markets. The market is expected to grow at a CAGR of 8.23% during the forecast period of 2025-2034, with the values likely to reach USD 5.40 Billion by 2034.
Neuroendocrine Tumours Treatment Market Overview
Neuroendocrine tumours (NETs) are a diverse group of neoplasms that arise from cells of the neuroendocrine system. These cells are found throughout the body, particularly in organs such as the gastrointestinal tract, pancreas, and lungs. Neuroendocrine cells are specialized cells that have characteristics of both nerve cells (neurons) and hormone-producing cells (endocrine cells). They produce hormones and release them into the bloodstream in response to signals from the nervous system.
The market for neuroendocrine tumours treatment has been growing steadily due to rising incidence rates globally and improved diagnostic capabilities. NETs are considered rare, but their recognition and diagnosis have been increasing, leading to a growing patient pool seeking treatment. The treatment options for NETs include surgery, chemotherapy, targeted therapy (such as somatostatin analogs and mTOR inhibitors), peptide receptor radionuclide therapy (PRRT), and others. The treatment market is driven by the increasing incidence of NETs, growing awareness among healthcare providers and patients, advancements in personalized medicine approaches, and ongoing clinical trials evaluating new therapies and combinations and driving the market growth.
Neuroendocrine Tumours Treatment Market Growth Drivers
Increasing Incidence and Awareness
As awareness about neuroendocrine tumours increase among healthcare providers and the general population, the scope of early detection is higher. Early detection is critical because NETs are often slow-growing and may not cause symptoms until they reach an advanced stage. Improved early detection leads to earlier intervention and treatment, which can potentially improve patient outcomes and survival rates.
There has been a documented increase in the incidence of neuroendocrine tumours globally. This increase is partly due to improvements in diagnostic techniques and surveillance, which have led to better recognition and reporting of NETs cases. Cancer Australia reported that 1 in 55 people were at risk of being diagnosed with neuroendocrine tumours by the age of 85 (1 in 52 for males and 1 in 58 for females) in 2022. As the number of diagnosed cases rises, there is a corresponding increase in the demand for treatment options and thus augmenting the market growth.
Expanding Treatment Options is Expected to Propel Neuroendocrine Tumours Treatment Market Demand
The treatment landscape for NETs has expanded with the introduction of targeted therapies such as somatostatin analogues, mTOR inhibitors, and peptide receptor radionuclide therapy (PRRT). These therapies offer more effective options compared to traditional chemotherapy, driving market growth as they become the standard of care in many regions.
Neuroendocrine Tumours Treatment Market Trends
The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:
Advancements in Targeted Therapies
There has been significant progress in the development of targeted therapies for NETs, such as somatostatin analogs, mTOR inhibitors, and peptide receptor radionuclide therapy (PRRT). These therapies are designed to specifically target the molecular pathways involved in NETs, leading to improved treatment outcomes and reduced side effects compared to traditional chemotherapy. These advancements are expected to drive the market growth.
Clinical Trials and Research Initiatives
The ongoing clinical trials and research efforts are expanding the understanding of NETs biology and evaluating novel therapeutic approaches. Research initiatives focus on exploring new drug targets, combination therapies, and immunotherapy strategies, which have the potential to further improve patient outcomes and expand the treatment landscape.
Rise in Strategic Partnerships
The neuroendocrine tumours treatment market is influenced by strategic mergers and acquisitions activities among manufacturers, healthcare providers, and technology companies that are driving innovation and fostering market expansion. These collaborations are accelerating the development of advanced products and augmenting the market reach globally.
Integration of Biomarkers
Biomarkers play a crucial role in diagnosing NETs, predicting treatment response, and monitoring disease progression. The integration of novel biomarkers into clinical practice is enhancing diagnostic accuracy and guiding treatment decisions. Biomarker-driven approaches also support the development of targeted therapies and companion diagnostics.
Neuroendocrine Tumours Treatment Market Segmentation
The EMR’s report titled “Neuroendocrine Tumours Treatment Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment
Market Segmentation Based on Treatment is Anticipated to Witness Substantial Growth
By treatment, the market is segmented into targeted therapy, chemotherapy, somatostatin analogues (SSAs) and others. The somatostatin analogues (SSAs) segment is dominating the market as somatostatin analogues such as octreotide and lanreotide are effective in controlling symptoms associated with functional NETs, such as carcinoid syndrome. These drugs work by inhibiting the secretion of hormones such as serotonin, histamine, and others, which are responsible for increasing its market share.
Neuroendocrine Tumours Treatment Market Analysis by Region
Based on the region, the market covers the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan and India. The United States is dominating the market share due to increasing technological innovations, along with a relatively high incidence and prevalence of neuroendocrine tumours compared to other regions. Improved diagnostic capabilities, increased awareness among healthcare providers, and enhanced surveillance contribute to the detection of more NET cases. This high disease burden drives the demand for effective treatment options in the region.
EU-4 also holds a high neuroendocrine tumours treatment market value due to its well-established infrastructure, specialized medical centres, and skilled healthcare professionals. The availability of comprehensive oncology services, including state-of-the-art imaging technologies, advanced surgical techniques, and access to clinical trials, supports the diagnosis and treatment of NETs at various stages and thus driving the regional demand.
Additionally, Japan and India are expected to witness substantial market growth, fueled by the growing patient pool suffering from diseases and increasing collaboration and funding initiatives.
Leading Players in the Neuroendocrine Tumours Treatment Market
The key features of the market report include patent analysis, clinical trials analysis, grant analysis, funding and investment analysis and other strategic initiatives by the leading players. The major companies in the market are as follows:
Pfizer Inc.
Pfizer Inc. has been involved in the research and development of treatments for various medical conditions, including neuroendocrine tumors (NETs). Pfizer has a vast portfolio that includes medications for oncology.
Novartis AG
Novartis AG is a pharmaceutical company actively involved in the research and development of treatments for various medical conditions, including neuroendocrine tumors (NETs).
Ipsen Pharma SA
Ipsen Pharma SA is actively involved in the field of neuroendocrine tumors (NETs) treatment through its oncology portfolio. Ipsen has developed and marketed several medications specifically for NETs. One notable example is Somatuline (lanreotide), which is used for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and carcinoid syndrome.
Other key players in the market include Abbvie Inc., AVEO Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, Hutchison MediPharma Limited, Tarveda Therapeutics, Progenics Pharmaceuticals, Inc., and Eli Lilly & Company among others.
Key Questions Answered in the Neuroendocrine Tumours Treatment Market Report
Neuroendocrine Tumours Treatment Market Overview
Neuroendocrine tumours (NETs) are a diverse group of neoplasms that arise from cells of the neuroendocrine system. These cells are found throughout the body, particularly in organs such as the gastrointestinal tract, pancreas, and lungs. Neuroendocrine cells are specialized cells that have characteristics of both nerve cells (neurons) and hormone-producing cells (endocrine cells). They produce hormones and release them into the bloodstream in response to signals from the nervous system.
The market for neuroendocrine tumours treatment has been growing steadily due to rising incidence rates globally and improved diagnostic capabilities. NETs are considered rare, but their recognition and diagnosis have been increasing, leading to a growing patient pool seeking treatment. The treatment options for NETs include surgery, chemotherapy, targeted therapy (such as somatostatin analogs and mTOR inhibitors), peptide receptor radionuclide therapy (PRRT), and others. The treatment market is driven by the increasing incidence of NETs, growing awareness among healthcare providers and patients, advancements in personalized medicine approaches, and ongoing clinical trials evaluating new therapies and combinations and driving the market growth.
Neuroendocrine Tumours Treatment Market Growth Drivers
Increasing Incidence and Awareness
As awareness about neuroendocrine tumours increase among healthcare providers and the general population, the scope of early detection is higher. Early detection is critical because NETs are often slow-growing and may not cause symptoms until they reach an advanced stage. Improved early detection leads to earlier intervention and treatment, which can potentially improve patient outcomes and survival rates.
There has been a documented increase in the incidence of neuroendocrine tumours globally. This increase is partly due to improvements in diagnostic techniques and surveillance, which have led to better recognition and reporting of NETs cases. Cancer Australia reported that 1 in 55 people were at risk of being diagnosed with neuroendocrine tumours by the age of 85 (1 in 52 for males and 1 in 58 for females) in 2022. As the number of diagnosed cases rises, there is a corresponding increase in the demand for treatment options and thus augmenting the market growth.
Expanding Treatment Options is Expected to Propel Neuroendocrine Tumours Treatment Market Demand
The treatment landscape for NETs has expanded with the introduction of targeted therapies such as somatostatin analogues, mTOR inhibitors, and peptide receptor radionuclide therapy (PRRT). These therapies offer more effective options compared to traditional chemotherapy, driving market growth as they become the standard of care in many regions.
Neuroendocrine Tumours Treatment Market Trends
The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:
Advancements in Targeted Therapies
There has been significant progress in the development of targeted therapies for NETs, such as somatostatin analogs, mTOR inhibitors, and peptide receptor radionuclide therapy (PRRT). These therapies are designed to specifically target the molecular pathways involved in NETs, leading to improved treatment outcomes and reduced side effects compared to traditional chemotherapy. These advancements are expected to drive the market growth.
Clinical Trials and Research Initiatives
The ongoing clinical trials and research efforts are expanding the understanding of NETs biology and evaluating novel therapeutic approaches. Research initiatives focus on exploring new drug targets, combination therapies, and immunotherapy strategies, which have the potential to further improve patient outcomes and expand the treatment landscape.
Rise in Strategic Partnerships
The neuroendocrine tumours treatment market is influenced by strategic mergers and acquisitions activities among manufacturers, healthcare providers, and technology companies that are driving innovation and fostering market expansion. These collaborations are accelerating the development of advanced products and augmenting the market reach globally.
Integration of Biomarkers
Biomarkers play a crucial role in diagnosing NETs, predicting treatment response, and monitoring disease progression. The integration of novel biomarkers into clinical practice is enhancing diagnostic accuracy and guiding treatment decisions. Biomarker-driven approaches also support the development of targeted therapies and companion diagnostics.
Neuroendocrine Tumours Treatment Market Segmentation
The EMR’s report titled “Neuroendocrine Tumours Treatment Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment
- Targeted Therapy
- Chemotherapy
- Somatostatin Analogues (SSAs)
- Other
- Oral
- Parenteral
- Gastrointestinal NET
- Lung NET
- Pancreatic NET
- Others
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Market Segmentation Based on Treatment is Anticipated to Witness Substantial Growth
By treatment, the market is segmented into targeted therapy, chemotherapy, somatostatin analogues (SSAs) and others. The somatostatin analogues (SSAs) segment is dominating the market as somatostatin analogues such as octreotide and lanreotide are effective in controlling symptoms associated with functional NETs, such as carcinoid syndrome. These drugs work by inhibiting the secretion of hormones such as serotonin, histamine, and others, which are responsible for increasing its market share.
Neuroendocrine Tumours Treatment Market Analysis by Region
Based on the region, the market covers the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan and India. The United States is dominating the market share due to increasing technological innovations, along with a relatively high incidence and prevalence of neuroendocrine tumours compared to other regions. Improved diagnostic capabilities, increased awareness among healthcare providers, and enhanced surveillance contribute to the detection of more NET cases. This high disease burden drives the demand for effective treatment options in the region.
EU-4 also holds a high neuroendocrine tumours treatment market value due to its well-established infrastructure, specialized medical centres, and skilled healthcare professionals. The availability of comprehensive oncology services, including state-of-the-art imaging technologies, advanced surgical techniques, and access to clinical trials, supports the diagnosis and treatment of NETs at various stages and thus driving the regional demand.
Additionally, Japan and India are expected to witness substantial market growth, fueled by the growing patient pool suffering from diseases and increasing collaboration and funding initiatives.
Leading Players in the Neuroendocrine Tumours Treatment Market
The key features of the market report include patent analysis, clinical trials analysis, grant analysis, funding and investment analysis and other strategic initiatives by the leading players. The major companies in the market are as follows:
Pfizer Inc.
Pfizer Inc. has been involved in the research and development of treatments for various medical conditions, including neuroendocrine tumors (NETs). Pfizer has a vast portfolio that includes medications for oncology.
Novartis AG
Novartis AG is a pharmaceutical company actively involved in the research and development of treatments for various medical conditions, including neuroendocrine tumors (NETs).
Ipsen Pharma SA
Ipsen Pharma SA is actively involved in the field of neuroendocrine tumors (NETs) treatment through its oncology portfolio. Ipsen has developed and marketed several medications specifically for NETs. One notable example is Somatuline (lanreotide), which is used for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and carcinoid syndrome.
Other key players in the market include Abbvie Inc., AVEO Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, Hutchison MediPharma Limited, Tarveda Therapeutics, Progenics Pharmaceuticals, Inc., and Eli Lilly & Company among others.
Key Questions Answered in the Neuroendocrine Tumours Treatment Market Report
- What was the neuroendocrine tumours treatment market value in 2023?
- What is the neuroendocrine tumours treatment market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on treatment?
- What is market segmentation based on the route of administration?
- What is market segmentation based on disease indication?
- What are the major factors aiding the neuroendocrine tumours treatment market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the major trends influencing the market?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How does the prevalence of neuroendocrine tumours affect the market landscape?
- How does the growing technological advancements in treatments impact the market size?
- Which disease indication area is expected to have a high market value in the coming years?
- Who are the key players involved in the neuroendocrine tumours treatment market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Neuroendocrine Tumours Treatment Market Overview: 8 Major Markets
- 3.1 Neuroendocrine Tumours Treatment Market Historical Value (2018-2024)
- 3.2 Neuroendocrine Tumours Treatment Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Neuroendocrine Tumours Treatment Market: Disease Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Therapy Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Therapy Success Rate
- 7 Neuroendocrine Tumours Treatment Market Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 U.S.
- 7.1.1.2 U.K.
- 7.1.1.3 EU4
- 7.1.1.4 India
- 7.1.1.5 Japan
- 7.1.2 Mortality by Country
- 7.1.2.1 U.S.
- 7.1.2.2 U.K.
- 7.1.2.3 EU4
- 7.1.2.4 India
- 7.1.2.5 Japan
- 7.1.3 Treatment Seeking Rate by Country
- 7.1.3.1 U.S.
- 7.1.3.2 U.K.
- 7.1.3.3 EU4
- 7.1.3.4 India
- 7.1.3.5 Japan
- 8 Neuroendocrine Tumours Treatment Market Landscape: 8 Major Market*
- 8.1 Neuroendocrine Tumours Treatment Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.2 Neuroendocrine Tumours Treatment Market: Product Landscape
- 8.2.1 Analysis by Type of Treatment
- 8.2.2 Analysis by Route of Administration
- 8.2.3 Analysis by Disease Indication
- 9 Neuroendocrine Tumours Treatment Market Therapy Challenges and Unmet Needs
- 9.1 Therapy Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Therapy
- 11 Neuroendocrine Tumours Treatment: Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Neuroendocrine Tumours Treatment Market Segmentation: 8 Major Market
- 12.1 Neuroendocrine Tumours Treatment Market by Treatment
- 12.1.1 Market Overview
- 12.1.2 Targeted Therapy
- 12.1.3 Chemotherapy
- 12.1.4 Somatostatin Analogues (SSAs)
- 12.1.5 Others
- 12.2 Neuroendocrine Tumours Treatment Market by Route of Administration
- 12.2.1 Market Overview
- 12.2.2 Oral
- 12.2.3 Parenteral
- 12.3 Neuroendocrine Tumours Treatment Market by Disease Indication
- 12.3.1 Market Overview
- 12.3.2 Gastrointestinal NET
- 12.3.3 Lung NET
- 12.3.4 Pancreatic NET
- 12.3.5 Others
- 12.4 Neuroendocrine Tumours Treatment Market by Region
- 12.4.1 Market Overview
- 12.4.2 United States
- 12.4.3 EU-4 and the United Kingdom
- 12.4.3.1 Germany
- 12.4.3.2 France
- 12.4.3.3 Italy
- 12.4.3.4 Spain
- 12.4.3.5 United Kingdom
- 12.4.4 Japan
- 12.4.5 India
- 13 United States Neuroendocrine Tumours Treatment Market (218-2034)
- 13.1 United States Neuroendocrine Tumours Treatment Market Historical Value (2018-2024)
- 13.2 United States Neuroendocrine Tumours Treatment Market Forecast Value (2025-2034)
- 13.3 United States Neuroendocrine Tumours Treatment Market by Treatment
- 13.3.1 Market Overview
- 13.3.2 Targeted Therapy
- 13.3.3 Chemotherapy
- 13.3.4 Somatostatin Analogues (SSAs)
- 13.3.5 Others
- 13.4 United States Neuroendocrine Tumours Treatment Market by Route of Administration
- 13.4.1 Market Overview
- 13.4.2 Oral
- 13.4.3 Parenteral
- 13.5 United States Neuroendocrine Tumours Treatment Market by Disease Indication
- 13.5.1 Market Overview
- 13.5.2 Gastrointestinal NET
- 13.5.3 Lung NET
- 13.5.4 Pancreatic NET
- 13.5.5 Others
- 14 EU-4 and United Kingdom Neuroendocrine Tumours Treatment Market (218-2034)
- 14.1 EU-4 and United Kingdom Neuroendocrine Tumours Treatment Market Historical Value (2018-2024)
- 14.2 EU-4 and United Kingdom Neuroendocrine Tumours Treatment Market Forecast Value (2025-2034)
- 14.3 EU-4 and United Kingdom Neuroendocrine Tumours Treatment Market by Treatment
- 14.3.1 Market Overview
- 14.3.2 Targeted Therapy
- 14.3.3 Chemotherapy
- 14.3.4 Somatostatin Analogues (SSAs)
- 14.3.5 Others
- 14.4 EU-4 and United Kingdom Neuroendocrine Tumours Treatment Market by Route of Administration
- 14.4.1 Market Overview
- 14.4.2 Oral
- 14.4.3 Parenteral
- 14.5 EU-4 and United Kingdom Neuroendocrine Tumours Treatment Market by Disease Indication
- 14.5.1 Market Overview
- 14.5.2 Gastrointestinal NET
- 14.5.3 Lung NET
- 14.5.4 Pancreatic NET
- 14.5.5 Others
- 15 Japan Neuroendocrine Tumours Treatment Market
- 15.1 Japan Neuroendocrine Tumours Treatment Market Historical Value (2018-2024)
- 15.2 Japan Neuroendocrine Tumours Treatment Market Forecast Value (2025-2034)
- 15.3 Japan Neuroendocrine Tumours Treatment Market by Treatment
- 15.3.1 Market Overview
- 15.3.2 Targeted Therapy
- 15.3.3 Chemotherapy
- 15.3.4 Somatostatin Analogues (SSAs)
- 15.3.5 Others
- 15.4 Japan Neuroendocrine Tumours Treatment Market by Route of Administration
- 15.4.1 Market Overview
- 15.4.2 Oral
- 15.4.3 Parenteral
- 15.5 Japan Neuroendocrine Tumours Treatment Market by Disease Indication
- 15.5.1 Market Overview
- 15.5.2 Gastrointestinal NET
- 15.5.3 Lung NET
- 15.5.4 Pancreatic NET
- 15.5.5 Others
- 16 India Neuroendocrine Tumours Treatment Market
- 16.1 India Neuroendocrine Tumours Treatment Market (2018-2034) Historical Value (2018-2024)
- 16.2 India Neuroendocrine Tumours Treatment Market (2018-2034) Forecast Value (2025-2034)
- 16.3 India Neuroendocrine Tumours Treatment Market by Treatment
- 16.3.1 Market Overview
- 16.3.2 Targeted Therapy
- 16.3.3 Chemotherapy
- 16.3.4 Somatostatin Analogues (SSAs)
- 16.3.5 Others
- 16.4 India Neuroendocrine Tumours Treatment Market by Route of Administration
- 16.4.1 Market Overview
- 16.4.2 Oral
- 16.4.3 Parenteral
- 16.5 India Neuroendocrine Tumours Treatment Market by Disease Indication
- 16.5.1 Market Overview
- 16.5.2 Gastrointestinal NET
- 16.5.3 Lung NET
- 16.5.4 Pancreatic NET
- 16.5.5 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 INDIA CDSCO
- 17.5 JAPAN PMDA
- 17.6 Others
- 18 Patent Analysis
- 18.1 Analysis by Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 18.7 Analysis by Key Players
- 19 Clinical Trial Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Grant Analysis
- 20.1 Analysis by Year
- 20.2 Analysis by Amount Awarded
- 20.3 Analysis by Issuing Authority
- 20.4 Analysis by Grant Product
- 20.5 Analysis by Funding Institute
- 20.6 Analysis by Departments
- 20.7 Analysis by Recipient Organization
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Type of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Strategic Initiatives
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Type of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share Analysis, By Region (Top 5 Companies)
- 23.2 Pfizer Inc.
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Mergers and Acquisitions
- 23.2.5 Certifications
- 23.3 Novartis AG
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Mergers and Acquisitions
- 23.3.5 Certifications
- 23.4 Ipsen Pharma SA
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Mergers and Acquisitions
- 23.4.5 Certifications
- 23.5 Abbvie Inc.
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Mergers and Acquisitions
- 23.5.5 Certifications
- 23.6 AVEO Pharmaceuticals, Inc.
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Mergers and Acquisitions
- 23.6.5 Certifications
- 23.7 BoehringerIngelheim International GmbH
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Mergers and Acquisitions
- 23.7.5 Certifications
- 23.8 Hutchison MediPharma Limited
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Mergers and Acquisitions
- 23.8.5 Certifications
- 23.9 Tarveda Therapeutics
- 23.9.1 Financial Analysis
- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Mergers and Acquisitions
- 23.9.5 Certifications
- 23.10 Progenics Pharmaceuticals, Inc.
- 23.10.1 Financial Analysis
- 23.10.2 Product Portfolio
- 23.10.3 Demographic Reach and Achievements
- 23.10.4 Mergers and Acquisitions
- 23.10.5 Certifications
- 23.11 Eli Lilly & Company
- 23.11.1 Financial Analysis
- 23.11.2 Product Portfolio
- 23.11.3 Demographic Reach and Achievements
- 23.11.4 Mergers and Acquisitions
- 23.11.5 Certifications
- 24 Neuroendocrine Tumours Treatment Market – Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
